Cellectar Biosciences, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Cellectar Biosciences, Inc. (CLRB) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $428.31 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- Cellectar Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $428.31K, a 24.25% decline year-over-year.
- Cellectar Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $451.87K, a 19.70% decline year-over-year.
- Cellectar Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $567.79K, a 62.99% decline year-over-year.
- Cellectar Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $565.39K, a 29.26% decline year-over-year.
- Cellectar Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $2.26M, a 47.02% decline from fiscal 2024.
- Cellectar Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $4.27M, a 77.27% increase from fiscal 2023.
- Cellectar Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $2.41M, a 65.89% increase from fiscal 2022.
- Cellectar Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $1.45M, a 29.25% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $428.31K 10-Q · filed 2026-08-13 | $880.17K derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $451.87K 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $2.26M 10-K · filed 2026-03-04 | |||
| 2025-09-30 | $567.79K 10-Q · filed 2025-11-13 | $1.13M derived: sum of 2 quarters · filed 2026-08-13 | $1.70M derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-06-30 | $565.39K 10-Q · filed 2026-08-13 | $1.13M derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $562.74K 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $4.27M 10-K · filed 2026-03-04 | |||
| 2024-09-30 | $1.53M 10-Q · filed 2025-11-13 | $2.33M derived: sum of 2 quarters · filed 2025-11-13 | $2.79M derived: sum of 3 quarters · filed 2025-11-13 | |
| 2024-06-30 | $799.25K 10-Q · filed 2025-11-13 | $1.25M derived: sum of 2 quarters · filed 2025-11-13 | ||
| 2024-03-31 | $454.36K 10-Q · filed 2025-11-13 | |||
| 2023-12-31 | $2.41M 10-K · filed 2025-03-13 | |||
| 2023-09-30 | $497.88K 10-Q · filed 2024-11-18 | $917.63K derived: sum of 2 quarters · filed 2024-11-18 | $1.33M derived: sum of 3 quarters · filed 2024-11-18 | |
| 2023-06-30 | $419.76K 10-Q · filed 2024-11-18 | $827.96K derived: sum of 2 quarters · filed 2024-11-18 | ||
| 2023-03-31 | $408.21K 10-Q · filed 2024-11-18 | |||
| 2022-12-31 | $1.45M 10-K/A · filed 2024-10-29 | |||
| 2022-09-30 | $367.76K 10-K/A · filed 2024-10-29 | $787.71K derived: sum of 2 quarters · filed 2024-10-29 | $1.09M derived: sum of 3 quarters · filed 2024-10-29 | |
| 2022-06-30 | $419.95K 10-K/A · filed 2024-10-29 | $723.76K derived: sum of 2 quarters · filed 2024-10-29 | ||
| 2022-03-31 | $303.81K 10-K/A · filed 2024-10-29 | |||
| 2021-12-31 | $1.12M 10-K · filed 2023-03-09 | |||
| 2021-09-30 | $421.16K 10-Q · filed 2022-11-03 | $621.78K derived: sum of 2 quarters · filed 2022-11-03 | $746.34K derived: sum of 3 quarters · filed 2022-11-03 | |
| 2021-06-30 | $200.62K 10-Q · filed 2022-11-03 | $325.18K derived: sum of 2 quarters · filed 2022-11-03 | ||
| 2021-03-31 | $124.56K 10-Q · filed 2022-11-03 | |||
| 2020-12-31 | $467.54K 10-K · filed 2022-03-21 | |||
| 2020-09-30 | $116.29K 10-Q · filed 2021-11-08 | $208.94K derived: sum of 2 quarters · filed 2021-11-08 | $353.08K derived: sum of 3 quarters · filed 2021-11-08 | |
| 2020-06-30 | $92.64K 10-Q · filed 2021-11-08 | $236.79K derived: sum of 2 quarters · filed 2021-11-08 | ||
| 2020-03-31 | $144.15K 10-Q · filed 2021-11-08 | |||
| 2019-12-31 | $866.79K 10-K · filed 2021-03-02 | |||
| 2019-09-30 | $149.77K 10-Q · filed 2020-11-09 | $451.25K derived: sum of 2 quarters · filed 2020-11-09 | $658.90K derived: sum of 3 quarters · filed 2020-11-09 | |
| 2019-06-30 | $301.47K 10-Q · filed 2020-11-09 | $509.13K derived: sum of 2 quarters · filed 2020-11-09 | ||
| 2019-03-31 | $207.65K 10-Q · filed 2020-11-09 | |||
| 2018-12-31 | $721.21K 10-K · filed 2020-03-09 | |||
| 2018-09-30 | $163.90K 10-Q · filed 2019-11-12 | $339.48K derived: sum of 2 quarters · filed 2019-11-12 | $512.91K derived: sum of 3 quarters · filed 2019-11-12 | |
| 2018-06-30 | $175.58K 10-Q · filed 2019-11-12 | $349.02K derived: sum of 2 quarters · filed 2019-11-12 | ||
| 2018-03-31 | $173.44K 10-Q · filed 2019-11-12 | |||
| 2017-12-31 | $758.76K 10-K · filed 2019-02-26 | |||
| 2017-09-30 | $176.32K 10-Q · filed 2018-11-13 | $407.41K derived: sum of 2 quarters · filed 2018-11-13 | $573.08K derived: sum of 3 quarters · filed 2018-11-13 | |
| 2017-06-30 | $231.09K 10-Q · filed 2018-11-13 | $396.76K derived: sum of 2 quarters · filed 2018-11-13 | ||
| 2017-03-31 | $165.67K 10-Q · filed 2018-11-13 | |||
| 2016-12-31 | $529.16K 10-K · filed 2018-03-21 | |||
| 2015-12-31 | $447.30K 10-K · filed 2017-03-15 | |||
| 2014-12-31 | $850.35K 10-K/A · filed 2016-10-20 | |||
| 2013-12-31 | $2.32M 10-K · filed 2015-05-20 | |||
| 2012-12-31 | $1.50M 10-K · filed 2014-03-19 | |||
| 2011-12-31 | $907.46K 10-K · filed 2014-03-19 | |||
| 2010-12-31 | $353.34K 10-K · filed 2014-03-19 | |||
| 2009-12-31 | $502.20K 10-K · filed 2014-03-19 | |||
| 2008-12-31 | $477.49K 10-K · filed 2014-03-19 | |||
| 2007-12-31 | $570.39K 10-K · filed 2014-03-19 | |||
| 2006-12-31 | $43.99K 10-K · filed 2014-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |